Literature DB >> 24165174

Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations.

Shawn H Macvane1, Jared L Crandon, David P Nicolau.   

Abstract

Pharmacodynamic profiling data of carbapenems for Acinetobacter spp. are sparse. This study aimed to determine the pharmacodynamic targets of carbapenems for Acinetobacter baumannii based on a range of percentages of the dosing interval in which free drug concentrations remained above the MIC (fT>MIC) in the neutropenic murine thigh infection model. fT>MIC values of 23.7%, 32.8%, and 47.5% resulted in stasis, 1-log reductions, and 2-log reductions in bacterial density after 24 h, respectively. The pharmacodynamic targets of carbapenems for A. baumannii demonstrated in vivo are similar to those of other Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24165174      PMCID: PMC3910748          DOI: 10.1128/AAC.02029-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

Review 2.  Treatment of Acinetobacter infections.

Authors:  Joel Fishbain; Anton Y Peleg
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

3.  Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

4.  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

Authors:  Christine T Ong; Pamela R Tessier; Chonghua Li; Charles H Nightingale; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2006-08-23       Impact factor: 2.803

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.

Authors:  Aryun Kim; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

7.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

Review 8.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 10.  Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.

Authors:  Lisa L Maragakis; Trish M Perl
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

View more
  10 in total

1.  Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.

Authors:  David C Griffith; Mojgan Sabet; Ziad Tarazi; Olga Lomovskaya; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 2.  Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Authors:  Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

3.  Pharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model.

Authors:  S S Bhagwat; H Periasamy; S S Takalkar; S R Palwe; H N Khande; M V Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.

Authors:  Qing-Tao Zhou; Bei He; Ning Shen; Ying Liang; Li-Na Sun
Journal:  Drugs Aging       Date:  2017-02       Impact factor: 3.923

6.  Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.

Authors:  Ya-Sung Yang; Yung-Chih Wang; Shu-Chen Kuo; Chung-Ting Chen; Chang-Pan Liu; Yuag-Meng Liu; Te-Li Chen; Yi-Tzu Lee
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

7.  Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.

Authors:  Yi-Tzu Lee; Mei-Chun Chiang; Shu-Chen Kuo; Yung-Chih Wang; I-Hsin Lee; Te-Li Chen; Ya-Sung Yang
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

8.  A Potential Combination Therapy of Berberine Hydrochloride With Antibiotics Against Multidrug-Resistant Acinetobacter baumannii.

Authors:  Xiaobo Li; Yanqing Song; Lina Wang; Guangbo Kang; Ping Wang; Huabing Yin; He Huang
Journal:  Front Cell Infect Microbiol       Date:  2021-03-25       Impact factor: 5.293

Review 9.  Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man.

Authors:  Angela V Berry; Joseph L Kuti
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

10.  Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem.

Authors:  Maria Sanz Codina; Milo Gatti; Carla Troisi; Giacomo Fornaro; Zeno Pasquini; Filippo Trapani; Andrea Zanoni; Fabio Caramelli; Pierluigi Viale; Federico Pea
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.